ScholarIQanswers from OpenAlex & ORCID
David I. Quinn
ResearcherPublications, citations & collaboration network
David I. Quinn is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does David I. Quinn have?
ScholarIQindexed works
David I. Quinn has 830 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does David I. Quinn have?
ScholarIQcitation count
David I. Quinn has 28,589 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of David I. Quinn?
ScholarIQh-index
David I. Quinn has an h-index of 78 in OpenAlex.
What is the i10-index of David I. Quinn?
ScholarIQi10-index
David I. Quinn has an i10-index of 268 in OpenAlex.
What is the ORCID of David I. Quinn?
ScholarIQorcid
The ORCID for David I. Quinn is on the source record.
What is the OpenAlex record for David I. Quinn?
ScholarIQopenalex
The OpenAlex for David I. Quinn is on the source record.
What are the most-cited papers on David I. Quinn?
ScholarIQmost cited works
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
Joaquim Bellmunt, Ronald de Wit, David J. Vaughn, Yves Fradet, Jae‐Lyun Lee, Lawrence Fong, Nicholas J. Vogelzang, Miguel Ángel Climent, Daniel P. Petrylak, Toni K. Choueiri, Andrea Necchi, Winald R. Gerritsen, Howard Gurney, David I. Quinn, Stéphane Culine, Cora N. Sternberg, Yabing Mai, Christian Poehlein, Rodolfo F. Perini, Dean F. Bajorin
Intermittent versus Continuous Androgen Deprivation in Prostate Cancer
Maha Hussain, Catherine M. Tangen, Donna L. Berry, Celestia S. Higano, E. David Crawford, Glenn Liu, George Wilding, Stephen M. Prescott, S.K. Sundaram, Eric J. Small, Nancy A. Dawson, Bryan Donnelly, Peter Venner, Ulka N. Vaishampayan, Paul F. Schellhammer, David I. Quinn, Derek Raghavan, Benjamin Ely, Carol M. Moinpour, Nicholas J. Vogelzang, Ian M. Thompson
Circulating Tumor Cell Counts Are Prognostic of Overall Survival in SWOG S0421: A Phase III Trial of Docetaxel With or Without Atrasentan for Metastatic Castration-Resistant Prostate Cancer
Amir Goldkorn, Benjamin Ely, David I. Quinn, Catherine M. Tangen, Louis M. Fink, Tong Xu, Przemyslaw Twardowski, Peter J. Van Veldhuizen, Neeraj Agarwal, Michael A. Carducci, J. Paul Monk, Ram H. Datar, Mark Garzotto, Philip C. Mack, Primo N. Lara, Celestia S. Higano, Maha Hussain, Ian M. Thompson, Richard J. Côté, Nicholas J. Vogelzang
Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
Thomas Powles, Piotr Tomczak, Se Hoon Park, Balaji Venugopal, Thomas Ferguson, Stefan N. Symeonides, Jaroslav Hájek, Howard Gurney, Yen‐Hwa Chang, Jae‐Lyun Lee, Naveed Sarwar, Antoine Thiery-Vuillemin, Marine Gross‐Goupil, Mauricio Mahave, Naomi B. Haas, Piotr Sawrycki, Joseph E. Burgents, Lei Xu, Kentaro Imai, David I. Quinn, Toni K. Choueiri, Piotr Tomczak, Toni K. Choueiri, Se Hoon Park, Balaji Venugopal, Thomas Ferguson, Jaroslav Hájek, Tzu-Ping Lin, Stefan N. Symeonides, Jae‐Lyun Lee, Piotr Sawrycki, Naomi B. Haas, Howard Gurney, Mauricio Mahave, Naveed Sarwar, Antoine Thiery-Vuillemin, Marine Gross‐Goupil, Christine Chevreau, John M. Burke, Gurjyot K. Doshi, Bohuslav Melichar, Delphine Topart, Stéphane Oudard, Evgeniy Kopyltsov, H. Hammers, David I. Quinn, Ajjai Alva, Juliana de Menezes, Adriano Gonçalves e Silva, Eric Winquist, Alketa Hamzaj, Giuseppe Procopio, Boguslawa Karaszewska, Ewa M. Nowakowska-Zajdel, B. Yа. Alekseev, Rustem Gafanov, А. А. Измайлов, Andrey Semenov, S. G. Afanasyev, Oleg Lipatov, T.B. Powles, Sandy Srinivas, David F. McDermott, Samith T. Kochuparambil, Ian D. Davis, Katriina Peltola, Roberto Sabbatini, Jinsoo Chung, М. I. Shkolnik, В. Б. Матвеев, P. Gajate Borau, Steven McCune, Thomas E. Hutson, Alejandro Dri, Silvio Correia Sales, Carrie Yeung, Carmen Marcela Alcala Castro, Peter J. Boström, Brigitte Laguerre, Consuelo Buttigliero, Ugo De Giorgi, Eugeniy A. Fomin, Yousef Zakharia, Clara Hwang, Eric A. Singer, Jeffrey T. Yorio, David Waterhouse, Rubén Dario Kowalyszyn, Margarita Sonia Alfie, Eduardo Yañez Ruiz, Tomáš Büchler, Krista Kankaanranta, G. Ferretti, Go Kimura, Kazuo Nishimura, Naoya Masumori, Satoshi Tamada, Haruaki Kato, Hiroshi Kitamura, Iwona Danielewicz
Axitinib versus placebo as an adjuvant treatment of renal cell carcinoma: results from the phase III, randomized ATLAS trial
Marine Gross‐Goupil, Tae‐Geon Kwon, Masatoshi Eto, Dingwei Ye, Hideaki Miyake, S.I. Seo, S.-S. Byun, Jia-Lin Lee, Viraj A. Master, Jie Jin, R. DeBenedetto, R. Linke, Michelle Casey, Brad Rosbrook, Mariajosé Lechuga, Olga Valota, Enrique Grande, David I. Quinn